Veliparibe, Paclitaxel e Carboplatina no tratamento de pacientes com tumores sólidos que são metastáticos ou não podem ser removidos por cirurgia e disfunção hepática ou renal
Um estudo inicial de fase 1 de ABT-888 em combinação com carboplatina e paclitaxel em pacientes com disfunção hepática ou renal e tumores sólidos
This phase I trial studies the side effects and the best dose of veliparib when given together with paclitaxel and carboplatin in treating patients with solid tumors that are metastatic or cannot be removed by surgery and liver or kidney dysfunction. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib together with paclitaxel and carboplatin may kill more tumor cells.
Visão geral do estudo
Status
Status
Condições
Condições
- Insuficiência hepática
- Melanoma
- Insuficiência renal
- Carcinoma de mama
- Carcinoma Endometrial
- Carcinoma Urotelial
- Carcinoma Pulmonar
- Neoplasia Sólida Maligna Metastática
- Carcinoma de Ovário
- Carcinoma Esofágico
- Neoplasia maligna irressecável
- Neoplasia Maligna de Cabeça e Pescoço
- Carcinoma de Primário Desconhecido
- Neoplasia testicular maligna
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
PRIMARY OBJECTIVES:
I. To determine the pharmacokinetics and pharmacodynamics of ABT-888 (veliparib) in patients with varying degrees of renal or hepatic dysfunction.
II. To determine the maximum tolerated dose (MTD) of ABT-888 in combination with carboplatin and paclitaxel for patients with varying degrees of liver or kidney dysfunction.
III. To provide dosing recommendations for ABT-888 in combination with carboplatin and paclitaxel based on degree of hepatic and renal impairment.
SECONDARY OBJECTIVES:
I. To define the dose-limiting toxicity (DLT) and other toxicities associated with the use of this combination in patients with varying degrees of renal or hepatic dysfunction.
II. To evaluate the pharmacokinetic parameters of ABT-888, carboplatin, and paclitaxel when administered as a combination in patients with varying degrees of renal or hepatic dysfunction.
III. To evaluate the pharmacodynamic measurement of poly-ADP-ribosylated (PAR) and platinum adducts in tumor cells associated with the use of this combination in patients with varying degrees of renal or hepatic dysfunction.
OUTLINE: This is a dose-escalation study of veliparib.
Patients receive veliparib* orally (PO) twice daily (BID) on days 1-7 and paclitaxel intravenously (IV) over 3 hours and carboplatin IV over 30 minutes on day 3. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
NOTE: * All patients receive a single dose of veliparib PO on day -6 before course 1 (except patients with very severe renal dysfunction who receive veliparib on day -5 or -6 to coincide with a dialysis day).
After completion of study treatment, patients are followed up for 4 weeks.
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Estágio
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
California
-
Duarte, California, Estados Unidos, 91010
- City of Hope Comprehensive Cancer Center
-
Sacramento, California, Estados Unidos, 95817
- University of California Davis Comprehensive Cancer Center
-
South Pasadena, California, Estados Unidos, 91030
- City of Hope South Pasadena
-
-
Florida
-
Tampa, Florida, Estados Unidos, 33612
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Emory University Hospital/Winship Cancer Institute
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Dana-Farber Cancer Institute
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48201
- Wayne State University/Karmanos Cancer Institute
-
-
New Jersey
-
New Brunswick, New Jersey, Estados Unidos, 08903
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
New York, New York, Estados Unidos, 10065
- Memorial Sloan Kettering Cancer Center
-
The Bronx, New York, Estados Unidos, 10467
- Montefiore Medical Center - Moses Campus
-
The Bronx, New York, Estados Unidos, 10461
- Montefiore Medical Center-Weiler Hospital
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44106
- Case Western Reserve University
-
-
Pennsylvania
-
Hershey, Pennsylvania, Estados Unidos, 17033-0850
- Penn State Milton S Hershey Medical Center
-
Pittsburgh, Pennsylvania, Estados Unidos, 15232
- UPMC Hillman Cancer Center
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- UT MD Anderson Cancer Center
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Patients must have histologically confirmed malignancy that is radiologically evaluable and metastatic or unresectable, for which standard curative or palliative measures do not exist or are no longer effective, and for which there is expectation of response to the combination of carboplatin/paclitaxel (i.e., lung, ovarian, breast, melanoma, head and neck, endometrial, urothelial, testicular, esophageal, carcinoma of unknown primary); for indications not listed, eligibility based on disease must be verified by the principal investigator before they are considered
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
- Life expectancy of greater than 12 weeks
- Absolute neutrophil count >= 1,500/mcL
- Platelets >= 100,000/mcL
- Hemoglobin >= 8.0 g/dL
- Patients with all degrees of renal dysfunction are allowed including patients on hemodialysis; patients with mild to severe hepatic dysfunction are allowed as defined below:
- Total bilirubin =< 5 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 10 x ULN
- For patients with a recently placed biliary stent, patients should have consistent results within a hepatic group from two laboratory readings within 3 days apart, taken at least 10 days following biliary stent placement; for patients with a biliary stent placed over 2 months ago, no obstruction or blockage can have occurred within the last 2 months
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those whose adverse event due to agents administered more than 4 weeks earlier have not resolved or stabilized; patients who have been administered ABT-888 as part of a single or combination, phase 0 or I study, should not necessarily be excluded from participating in this study solely because of receiving prior ABT-888
- Patients may not be receiving any other investigational agents
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to ABT-888 or other agents used in study
- Peripheral neuropathy of severity greater than grade 1
- Inability to take oral medications on a continuous basis
- Evidence of bleeding diathesis
- Patients with central nervous system (CNS) metastases must be stable after therapy for CNS metastases (such as surgery, radiotherapy or stereotactic radiosurgery) for at least 3 months and must be off steroid treatment prior to study enrollment
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with ABT-888; these potential risks may also apply to other agents used in this study
- Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; however, HIV-positive patients without an acquired immune deficiency syndrome (AIDS)-defining diagnosis who are not receiving agents with the potential for pharmacokinetic (PK) interactions with ABT-888 may be eligible
- Patients with both hepatic and renal dysfunction will also be excluded
- Patients who received and progressed on the combination of carboplatin/paclitaxel will not be eligible
- Active seizure or history of seizure disorder
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Treatment (veliparib, paclitaxel, carboplatin)
Patients receive veliparib* PO BID on days 1-7 and paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 3. Courses repeat every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. NOTE: * All patients receive a single dose of veliparib PO on day -6 before course 1 (except patients with very severe renal dysfunction who receive veliparib on day -5 or -6 to coincide with a dialysis day). |
Given IV
Outros nomes:
Given IV
Outros nomes:
Correlative studies Given PO
Outros nomes:
Correlative studies |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
MTD de veliparibe em combinação com carboplatina e paclitaxel, determinado de acordo com a incidência de DLT conforme classificado usando o National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) versão (v) 4.0
Prazo: 21 dias
|
21 dias
|
|
|
PK parameters of veliparib
Prazo: Day -6 and 3 of course 1 after veliparib dosing
|
Standard quantitative and graphical statistical summaries of the derived PK parameters (e.g. area under curve and clearance) will be produced for each organ function cohort. The effect of dysfunction on pharmacokinetics will be explored by comparing each pharmacokinetic parameter across all cohorts using one-way analysis (analysis of variance) or Kruskal-Wallis test. The level of each protein will be compared between responders and non-responders using the Wilcoxon signed rank test. |
Day -6 and 3 of course 1 after veliparib dosing
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of toxicities as assessed by NCI CTCAE v4.0
Prazo: Up to 4 weeks after completion of study treatment
|
The maximum grade of toxicity for each category of interest will be recorded for each patient and the summary results will be tabulated by category, grade and dose level. Severe and life-threatening toxicities and adverse event-related deaths (>= grade 3) will be described on a patient-by-patient basis and will include any relevant baseline data. |
Up to 4 weeks after completion of study treatment
|
|
Response rate as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Prazo: Up to 4 weeks after completion of study treatment
|
Responses will be tabulated by disease diagnosis and by dose level. 95% confidence limits will also be reported on the response rates. |
Up to 4 weeks after completion of study treatment
|
|
Incidence of stable disease as assessed by RECIST version 1.1
Prazo: Up to 4 weeks after completion of study treatment
|
Incidence of stable disease will be tabulated by disease diagnosis and by dose level. |
Up to 4 weeks after completion of study treatment
|
|
Time to progression
Prazo: Up to 4 weeks after completion of study treatment
|
Displayed for all patients and for patients who have responded; no formal statistical analysis is planned. |
Up to 4 weeks after completion of study treatment
|
Outras medidas de resultado
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in PAR levels
Prazo: Baseline to up to 4 weeks
|
Descriptive statistics (mean, standard deviation, median, range) for measurements of PAR levels will provided with 95% confidence intervals (CIs). When sample size permits, a formal statistical test using the Wilcoxon signed rank test will be used to compare the post treatment PAR levels to the baseline levels. When feasible, the level will be compared between responders and non-responders using the Wilcoxon signed rank test. |
Baseline to up to 4 weeks
|
|
Change in gamma-H2AX levels
Prazo: Baseline to up to 4 weeks
|
Descriptive statistics (mean, standard deviation, median, range) for measurements of gamma-H2AX levels will provided with 95% CIs. When sample size permits, a formal statistical test using the Wilcoxon signed rank test will be used to compare the post treatment PAR levels to the baseline levels. When feasible, the level will be compared between responders and non-responders using the Wilcoxon signed rank test. |
Baseline to up to 4 weeks
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Hussein A Tawbi, University of Pittsburgh Cancer Institute (UPCI)
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Real)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimado)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças Genitais
- Doenças do Sistema Endócrino
- Processos Patológicos
- Neoplasias Genitais Masculinas
- Neoplasias urogenitais
- Neoplasias por local
- Neoplasias
- Doenças Genitais, Masculino
- Doenças Urogenitais Masculinas
- Doenças renais
- Doenças Urológicas
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Doenças Respiratórias
- Neoplasias por Tipo Histológico
- Neoplasias gastrointestinais
- Neoplasias do Aparelho Digestivo
- Doenças do aparelho digestivo
- Doenças Gastrointestinais
- Doenças uterinas
- Doenças Genitais Femininas
- Doenças pulmonares
- Neoplasias das Glândulas Endócrinas
- Doenças do Fígado
- Neoplasias Glandulares e Epiteliais
- Neoplasias do Trato Respiratório
- Neoplasias Torácicas
- Processos Neoplásicos
- Doenças Esofágicas
- Doenças ovarianas
- Doenças anexiais
- Neoplasias Genitais Femininas
- Distúrbios Gonadais
- Doenças de pele
- Doenças da mama
- Carcinoma
- Tumores Neuroectodérmicos
- Neoplasias, Células Germinativas e Embrionárias
- Neoplasias, Tecido Nervoso
- Neoplasias uterinas
- Tumores Neuroendócrinos
- Nevos e Melanomas
- Neoplasias Cutâneas
- Insuficiência Hepática
- Doenças testiculares
- Condições Patológicas, Sinais e Sintomas
- Doenças da Pele e do Tecido Conjuntivo
- Neoplasias Pulmonares
- Neoplasias Esofágicas
- Neoplasias ovarianas
- Neoplasias da Mama
- Neoplasia Metástase
- Neoplasias de Cabeça e Pescoço
- Melanoma
- Neoplasias endometriais
- Insuficiência renal
- Carcinoma de Células de Transição
- Insuficiência hepática
- Neoplasias Primárias Desconhecidas
- Neoplasias testiculares
- Produtos químicos orgânicos
- Hidrocarbonetos
- Cicloparaffinas
- Hidrocarbonetos, aliciclicos
- Hidrocarbonetos, cíclicos
- Terpenos
- Complexos de coordenação
- Taxóides
- Ciclodecanos
- Diterpenos
- Economia de saúde e organizações
- Economia
- Carboplatina
- Paclitaxel
- Veliparibe
- Impostos
Outros números de identificação do estudo
Outros números de identificação do estudo
- NCI-2011-02500
- U01CA070095 (Concessão/Contrato do NIH dos EUA)
- UM1CA186691 (Concessão/Contrato do NIH dos EUA)
- UM1CA186716 (Concessão/Contrato do NIH dos EUA)
- U01CA099168 (Concessão/Contrato do NIH dos EUA)
- U01CA062502 (Concessão/Contrato do NIH dos EUA)
- U01CA062505 (Concessão/Contrato do NIH dos EUA)
- U01CA062490 (Concessão/Contrato do NIH dos EUA)
- U01CA069856 (Concessão/Contrato do NIH dos EUA)
- UM1CA186690 (Concessão/Contrato do NIH dos EUA)
- UM1CA186717 (Concessão/Contrato do NIH dos EUA)
- UM1CA186709 (Concessão/Contrato do NIH dos EUA)
- N01CM00100 (Concessão/Contrato do NIH dos EUA)
- P30CA047904 (Concessão/Contrato do NIH dos EUA)
- NCI-2011-02500 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- CDR0000700997
- UPCI 10-115
- UPCI-10-115
- 8808 (Outro identificador: CTEP)
- 8808 (Outro identificador: UPMC Hillman Cancer Center)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .